Galapagos Nv

Polaris Pharmaceuticals, Inc.

Burritt, Andrew

Xueliang Tao

Martin James Inglis Andrews

Paul John Edwards

Sébastien Laurent Xavier Martina

Friedrich Erich Karl Kroll

Andrew Burritt

Stephen Evan Webber

Wolfgang Schmidt

Grégory Louis Joseph Bar

Veronique Birault

Elena Brin

Brigitte Allart

The present invention provides synthesis, pharmaceutically acceptable formulations and uses of compounds in accordance with Formula (I), or a stereoisomer, a tautomer or a pharmaceutically acceptable salt thereof. For Formula (I) compounds R, R, R, Ar and Z are as defined in the specification. The inventive Formula (I) compounds are inhibitors of CK2 and find utility in any number of therapeutic applications, including but not limited to treatment of proliferative disorders such as cancer, inflammation and immunological disorders.

CK2 inhibitors, compositions and methods thereof

Novel triazolopyridine compounds are disclosed that have a formula represented by the following: The compounds may be prepared as pharmaceutical compositions, and may be used for the prevention and treatment of a variety of conditions in mammals including humans, including by way of non-limiting example, ECM degradation, joint degradation and/or inflammation, and others.

Triazolopyridine compounds useful for the treatment of degenerative and inflammatory diseases

Novel imidazolopyridine compounds are disclosed that have a formula represented by the following:  The compounds may be prepared as pharmaceutical compositions, and may be used for the prevention and treatment of a variety of conditions in mammals including humans, including by way of non-limiting example, ECM degradation, joint degradation and/or inflammation, and others.

Imidazolopyridine compounds useful for the treatment of degenerative and inflammatory diseases

Growing community of inventors

San Diego, CA, United States of America

Xueliang Tao